A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage

Laboratory Investigation

Volumn 80, Issue 3, 2000, Pages 335-344

  Blok, Vanessa T ^a   Daha, Mohamed R ^a   Tijsma, Odette M H ^a   Weissglas, M Geer ^a   Van Den Broek, Lambert J C M ^a   Gorter, Arko ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5B; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; REGULATOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CELL PROTECTION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 0034033511     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780038     Document Type: Article

References (37)

1. Azuma A, Yamano Y, Yoshimura A, Hibino T, Nishida T, Yagita H, Okumura K, Seya T, Kannagi R, Shibuya M, and Kudoh S (1995). Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins. Scand J Immunol 42:202-208.
2. Bander NH, Finstad CL, Cordon Cardo C, Ramsawak RD, Vaughan ED, Jr., Whitmore WF, Jr., Oettgen HF, Melamed MR, and Old LJ (1989). Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res 49:6774-6780.
3. Bara S and Lint TF (1987). The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages. J Immunol 138: 1303-1309.
4. Bjørge L, Hakulinen J, Wahlström T, Matre R, and Meri S (1997). Complement-regulatory proteins in ovarian malignancies. Int J Cancer 70:14-25.
5. Blok VT, Dana MR, Tijsma O, Harris CL, Morgan BP, Fleuren GJ, and Gorter A (1998). Bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 160:3437-3443.
6. Bono AV and Lovisolo JAJ (1997). Renal cell carcinoma-Diagnosis and treatment: State of the art. Eur Urol 31:47-55.
7. Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A, and Maio M (1995). Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 61:548-556.
8. Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, and Maio M (1996). Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 74:33-42.
9. Bukowski RM (1997). Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198-1220.
10. Bukowski RM, Olencki T, Wang Q, Peereboom D, Budd GT, Elson P, Sandstrom K, Tuason L, Rayman P, Tubbs R, McLain D, Klein E, Novick A, and Finke J (1997). Phase II trial of interleukin-2 and interferon-a in patients with renal cell carcinoma: Clinical results and immunologic correlates of response. J Immunother 20:301-311.
11. Cheung N-KV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, and Medof ME (1988). Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81:1122-1128.
12. Devaux P, Christiansen D, Fontaine M, and Gerlier D (1999). Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur J Immunol 29:815-822.
13. Dillman RO (1994). Antibodies as cytotoxic therapy. J Clin Oncol 12:1497-1515.
14. Figlin RA (1999). Renal cell carcinoma: Management of advanced disease. J Urol 161:381-386.
15. Fuhrman SA, Lasky LC, and Limas C (1982). Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663.
16. Gorter A, Blok VT, Haasnoot WHB, Ensink NG, Daha MR, and Fleuren GJ (1996). Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complemented-mediated tumor cell lysis. Lab Invest 74: 1039-1049.
17. Gorter A and Meri S (1999). Immune evasion of tumor cells using membrane-bound regulatory proteins. Immunol Today 20:576-582.
18. th ed. Berlin, Heidelberg, New York: Springer-Verlag, 296-302.
19. Holthöfer H, Miettinen A, Paasivuo R, Lehto VP, Linder E, Alfthan O, and Virtanen I (1983). Cellular origin and differentiation of renal carcinomas. A fluorescence microscopic study with kidney-specific antibodies, antiintermediate filament antibodies, and lectins. Lab Invest 49:317-326.
20. Hrouda D, Muir GH, and Dalgleish AG (1997). The role of immunotherapy for urological tumours. Br J Urol 79:307-316.
21. Ichida S, Yuzawa Y, Okada H, Yoshioka K, and Matsuo S (1994). Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46:89-96.
22. Kumar S, Vinci JM, Pytel BA, and Baglioni C (1993). Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 53:348-353.
23. Liszewski MK, Farries TC, Lublin DM, Rooney IA, and Atkinson JP (1996). Control of the complement system. Adv Immunol 61:201-283.
24. Mäenpää A, Junnikkala S, Hakulinen J, Timonen T, and Meri S (1996). Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 148:1139-1152.
25. Motzer RJ, Bander NH, and Nanus DM (1996). Renal-cell carcinoma. N Engl J Med 335:865-875.
26. Nakanishi I, Moutabarrik A, Hara T, Hatanaka M, Hayashi T, Syouji T, Okada N, Kitamura E, Tsubakihara Y, Matsumoto M, and Seya T (1994). Identification and characterization of membrane cofactor protein (CD46) in the human kidneys. Eur J Immunol 24:1529-1535.
27. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, and Dalmasso AP (1996). Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149:129-142.
28. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EKJ, Jonas U, Zwartendijk J, and Warnaar SO (1986). Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 38:489-494.
29. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF, and Old LJ (1993). Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 11:738-750.
30. Pittman K and Selby P (1994). The management of renal cell carcinoma. Crit Rev Oncol Hematol 16:181-200.
31. Ruiter DJ, Ferrier CM, Van Muijen GNP, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS, Schmitt M, and Eur BIOMED-1 Concert Act Clin Relev (1998). Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. Eur J Cancer 34:1334-1340.
32. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GON, Witjes JA, Koenders EB, Oyen WJG, Buijs WCAM, Debruyne FMJ, Corstens FHM, and Oosterwijk E (1997). Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 15:1529-1537.
33. Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, and Iczkowski K (1997). Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:987-989.
34. Terachi T, Stanescu G, Pontes JE, Medof ME, and Caulfield MJ (1991). Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells. Cancer Res 51:2521-2523.
35. + macrophages in antitumor cytotoxicity. Lab Invest 67:166-174.
36. Varsano S, Frolkis I, and Ophir D (1995). Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. Am J Respir Crit Care Med 152:1087-1093.
37. Venneker GT, Vodegel RM, Okada N, Westerhof W, Bos JD, and Asghar SS (1998). Relative contributions of decoy accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement. Immunobiology 198:476-484.